Page last updated: 2024-10-14

golotimod

Description

golotimod: a synthetic dipeptide that stimulates immune system activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6992140
CHEMBL ID2103812
CHEBI ID177459
SCHEMBL ID727944
MeSH IDM0444429

Synonyms (41)

Synonym
229305-39-9
(2r)-2-amino-5-[[(1s)-2-hydroxy-1-(1h-indol-3-ylmethyl)-2-oxo-ethyl]amino]-5-oxo-pentanoic acid
(gamma-glutamyl-l-tryptophan)
golotimod
gamma-d-glu-l-trp
scv 07
scv07
scv-07
D08928
golotimod (usan/inn)
golotimod [usan:inn]
637c487y09 ,
l-tryptophan, d-gamma-glutamyl-
gamma-d-glutamyl-l-tryptophan
(2r)-2-amino-5-(((1s)-1-carboxy-2-(1h-indol-3-yl)ethyl)amino)-5-oxopentanoic acid
unii-637c487y09
CHEMBL2103812
d-.gamma.-glutamyl-l-tryptophan
(2r)-2-amino-5-[[(1s)-1-carboxy-2-(1h-indol-3-yl)ethyl]amino]-5-oxopentanoic acid
golotimod [usan]
golotimod [who-dd]
golotimod [inn]
DB05475
SCHEMBL727944
DTXSID10177474
CHEBI:177459
mfcd28137704
CATMPQFFVNKDEY-YPMHNXCESA-N
h-d-glu(l-trp-oh)-oh
AKOS030573318
BCP24651
h-d-glu(l-trp-oh)-oh;scv 07;gamma-d-glu-l-trp;scv-07;scv07
(r)-2-amino-5-(((s)-1-carboxy-2-(1h-indol-3-yl)ethyl)amino)-5-oxopentanoic acid
Q27095684
golotimod (scv-07)
HY-14743
CS-0003532
nsc-755401
nsc755401
h-gamma-d-glu-trp-oh; bestim
MS-25023
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (71.43)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (14.29%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]